Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-12-28

Clinical Trial Update: tAN to Mitigate Withdrawal Behaviors in Neonates [NA]

View source ↗

Summary

A completed clinical trial evaluating tAN to mitigate withdrawal behaviors in neonates with Neonatal Abstinence Syndrome; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • tAN®

Snippet

Sponsor: Spark Biomedical, Inc. | Conditions: Neonatal Abstinence Syndrome | NA | Status: COMPLETED | Results posted: 2022-12-28